Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology

Journal of Controlled Release

Volumn 155, Issue 2, 2011, Pages 237-247

  Milane, Lara ^a   Ganesh, Shanthi ^a   Shah, Shruti ^a   Duan, Zhen Feng ^b   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer initiating (stem) cells; Multidrug resistance; Multifunctional nanoparticles; Tumor hypoxia; Warburg's effect

Indexed keywords

CANCER-INITIATING (STEM) CELLS; MULTI-FUNCTIONAL NANOPARTICLES; MULTIDRUG RESISTANCE; TUMOR HYPOXIA; WARBURG'S EFFECT; APOPTOTIC; DELIVERY VEHICLE; DRUG RESISTANCE; EPR EFFECT; MULTI-FUNCTIONAL NANOCARRIERS; MULTI-MODAL; NANO-SIZED; NANOCARRIERS; PHYSICAL APPROACHES; PRIMARY MECHANISM; SELECTION PRESSURES; THERAPEUTIC INDEX; TUMOR ACCUMULATION; TUMOR MASS; UP-REGULATION; VASCULATURE; WARBURG EFFECTS;

CHEMOTHERAPY; DISEASES; DRUG DELIVERY; STEM CELLS;

TUMORS;

ADAMANTANE; CERAMIDE; DENDRIMER; DOXORUBICIN; GELATIN; GOLD NANOPARTICLE; IRON OXIDE; LIPOSOME; MACROGOL; NANOCARRIER; PACLITAXEL; PHOTOFRIN; POLYCAPROLACTONE; POLYMER; QUANTUM DOT; SUPEROXIDE DISMUTASE; TAMOXIFEN; VERAPAMIL; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; RNA;

BLADDER CANCER; CANCER RESISTANCE; CANCER THERAPY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TARGETING; ESOPHAGUS CANCER; GENE SILENCING; GENE TARGETING; HUMAN; HYPERTHERMIC THERAPY; IMMUNE RESPONSE; LUNG CANCER; MICELLE; MULTIDRUG RESISTANCE; NANOEMULSION; NANOENGINEERING; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE; ULTRASOUND; APOPTOSIS; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; HUMAN CELL; HYPOXIA; NANOMOTOR; STEM CELL; TUMOR RESISTANCE; TUMOR VOLUME;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL HYPOXIA; COMBINED MODALITY THERAPY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLYCOLYSIS; HUMANS; NANOTECHNOLOGY; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 80054103346     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.03.032     Document Type: Conference Paper

References (125)

1. A.L. Harris, and D. Hochhauser Mechanisms of multidrug resistance in cancer treatment Acta Oncol. 31 2 1992 205 213
2. K. Jamroziak, and T. Robak Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies Hematology 9 2 2004 91 105 (Pubitemid 38697023)
3. J.C. Leighton Jr., and L.J. Goldstein P-glycoprotein in adult solid tumors. Expression and prognostic significance Hematol. Oncol. Clin. North Am. 9 2 1995 251 273
4. O. Tredan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst. 99 19 2007 1441 1454
5. T. Tsuruo, M. Naito, A. Tomida, N. Fujita, T. Mashima, H. Sakamoto, and N. Haga Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal Cancer Sci. 94 1 2003 15 21 (Pubitemid 36575852)
6. E. Yague, A. Arance, L. Kubitza, M. O'Hare, P. Jat, C.M. Ogilvie, I.R. Hart, C.F. Higgins, and S. Raguz Ability to acquire drug resistance arises early during the tumorigenesis process Cancer Res. 67 3 2007 1130 1137
7. D.A. Nelson, T.T. Tan, A.B. Rabson, D. Anderson, K. Degenhardt, and E. White Hypoxia and defective apoptosis drive genomic instability and tumorigenesis Genes Dev. 18 17 2004 2095 2107 (Pubitemid 39166627)
8. R. Depping, A. Steinhoff, S.G. Schindler, B. Friedrich, R. Fagerlund, E. Metzen, E. Hartmann, and M. Kohler Nuclear translocation of hypoxia-inducible factors (HIFs): involvement of the classical importin alpha/beta pathway Biochim. Biophys. Acta 1783 3 2008 394 404
9. A.L. Harris Hypoxia - a key regulatory factor in tumour growth Nat. Rev. 2 1 2002 38 47 (Pubitemid 37328806)
10. G.L. Semenza Targeting HIF-1 for cancer therapy Nat. Rev. 3 10 2003 721 732 (Pubitemid 37328811)
11. M.C. Brahimi-Horn, J. Chiche, and J. Pouyssegur Hypoxia and cancer J. Mol. Med. 85 12 2007 1301 1307 (Pubitemid 50004093)
12. J.P. Cosse, and C. Michiels Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression Anticancer Agents Med. Chem. 8 7 2008 790 797
13. U.R. Jewell, I. Kvietikova, A. Scheid, C. Bauer, R.H. Wenger, and M. Gassmann Induction of HIF-1 alpha in response to hypoxia is instantaneous FASEB J. 15 7 2001 1312 1314
14. S. Kizaka-Kondoh, M. Inoue, H. Harada, and M. Hiraoka Tumor hypoxia: a target for selective cancer therapy Cancer Sci. 94 12 2003 1021 1028 (Pubitemid 38035514)
15. J. Nanduri, G. Yuan, G.K. Kumar, G.L. Semenza, and N.R. Prabhakar Transcriptional responses to intermittent hypoxia Respir. Physiol. Neurobiol. 164 1-2 2008 277 281
16. G.L. Semenza Hypoxia-inducible factor 1 and cancer pathogenesis IUBMB Life 60 9 2008 591 597
17. A.M. Shannon, D.J. Bouchier-Hayes, C.M. Condron, and D. Toomey Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies Cancer Treat. Rev. 29 4 2003 297 307 (Pubitemid 37069660)
18. M. Guppy The hypoxic core: a possible answer to the cancer paradox Biochem. Biophys. Res. Commun. 299 4 2002 676 680 (Pubitemid 36040368)
19. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. 2 1 2002 48 58 (Pubitemid 37328807)
20. D.M. Brizel, S.P. Scully, J.M. Harrelson, L.J. Layfield, J.M. Bean, L.R. Prosnitz, and M.W. Dewhirst Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res. 56 5 1996 941 943 (Pubitemid 26065381)
21. J.M. Brown Tumor hypoxia, drug resistance, and metastases J. Natl. Cancer Inst. 82 5 1990 338 339
22. M. Hockel, K. Schlenger, S. Hockel, and P. Vaupel Hypoxic cervical cancers with low apoptotic index are highly aggressive Cancer Res. 59 18 1999 4525 4528 (Pubitemid 29428951)
23. M. Nordsmark, M. Overgaard, and J. Overgaard Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck Radiother. Oncol. 41 1 1996 31 39 (Pubitemid 26396294)
24. S.D. Young, and R.P. Hill Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential J. Natl. Cancer Inst. 82 5 1990 371 380 (Pubitemid 20108027)
25. J.P. Gillet, T. Efferth, and J. Remacle Chemotherapy-induced resistance by ATP-binding cassette transporter genes Biochim. Biophys. Acta 1775 2 2007 237 262 (Pubitemid 46899341)
26. L.W. Chinn, and D.L. Kroetz ABCB1 pharmacogenetics: progress, pitfalls, and promise Clin. Pharmacol. Ther. 81 2 2007 265 269 (Pubitemid 46174824)
27. T.P. Buys, R. Chari, E.H. Lee, M. Zhang, C. MacAulay, S. Lam, W.L. Lam, and V. Ling Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells Genes Chromosomes Cancer 46 12 2007 1069 1079 (Pubitemid 47614541)
28. Y. Kimura, S. Morita, M. Matsuo, and K. Ueda Mechanism of multidrug recognition by MDR1/ABCB1 Cancer Sci. 98 9 2007 1303 1310
29. C. Lemos, G. Jansen, and G.J. Peters Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors Br. J. Cancer 98 5 2008 857 862 (Pubitemid 351341599)
30. V.S. Donnenberg, and A.D. Donnenberg Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis J. Clin. Pharmacol. 45 8 2005 872 877 (Pubitemid 41060226)
31. Z.B. Han, H. Ren, H. Zhao, Y. Chi, K. Chen, B. Zhou, Y.J. Liu, L. Zhang, B. Xu, B. Liu, R. Yang, and Z.C. Han Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF) Carcinogenesis 29 10 2008 1853 1861
32. S. Hede, and N. Huilgol "Nano": the new nemesis of cancer J. Cancer Res. Ther. 2 4 2006 186 195
33. S.M. Moghimi, A.C. Hunter, and J.C. Murray Nanomedicine: current status and future prospects FASEB J. 19 3 2005 311 330 (Pubitemid 40316520)
34. G. Thornton Materials science. Watching nanoparticles grow Science 300 5624 2003 1378 1379 (Pubitemid 36638146)
35. V.V.S., and V.V. Pokropivny New dimensionality classifications of nanostructures Phys. E 40 2008 2521 2525
36. W.C. Hahn, and R.A. Weinberg Modelling the molecular circuitry of cancer Nat. Rev. Cancer 2 5 2002 331 341 (Pubitemid 37328946)
37. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 1 2000 57 70 (Pubitemid 30046295)
38. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2 2001 283 318 (Pubitemid 32476118)
39. R. Sinha, G.J. Kim, S. Nie, and D.M. Shin Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery Mol. Cancer Ther. 5 8 2006 1909 1917 (Pubitemid 44336561)
40. H. Maeda, J. Fang, T. Inutsuka, and Y. Kitamoto Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications Int. Immunopharmacol. 3 3 2003 319 328 (Pubitemid 36293960)
41. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 9 2008 771 782
42. J. Kope ek, P. Kope kov, T. Minko, Z. Lu, and C. Peterson Water soluble polymers in tumor targeted delivery J. Control. Release 74 1-3 2001 147 158 (Pubitemid 32727617)
43. F. Shen, S. Chu, A. Bence, B. Bailey, X. Xue, P. Erickson, M. Montrose, W. Beck, and L. Erickson Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells J. Pharmacol. Exp. Ther. 324 1 2008 95
44. J. Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, and R.J. Lee Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil J. Pharm. Pharm. Sci. 10 3 2007 350 357 (Pubitemid 350065179)
45. A.D. Judge, M. Robbins, I. Tavakoli, J. Levi, L. Hu, A. Fronda, E. Ambegia, K. McClintock, and I. MacLachlan Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice J. Clin. Invest. 119 3 2009 661 673
46. S. Nie, Y. Xing, G.J. Kim, and J.W. Simons Nanotechnology applications in cancer Annu. Rev. Biomed. Eng. 9 2007 257 288 (Pubitemid 350246658)
47. C.P. Leamon, and P.S. Low Folate-mediated targeting: from diagnostics to drug and gene delivery Drug Discov. Today 6 1 2001 44 51 (Pubitemid 32156966)
48. C.P. Leamon, and J.A. Reddy Folate-targeted chemotherapy Adv. Drug Deliv. Rev. 56 8 2004 1127 1141 (Pubitemid 38496512)
49. J.A. Reddy, and P.S. Low Folate-mediated targeting of therapeutic and imaging agents to cancers Crit. Rev. Ther. Drug Carrier Syst. 15 6 1998 587 627 (Pubitemid 29006581)
50. B. Stella, S. Arpicco, M.T. Peracchia, D. Desmaele, J. Hoebeke, M. Renoir, J. D'Angelo, L. Cattel, and P. Couvreur Design of folic acid-conjugated nanoparticles for drug targeting J. Pharm. Sci. 89 11 2000 1452 1464
51. L.E. van Vlerken, and M.M. Amiji Multi-functional polymeric nanoparticles for tumour-targeted drug delivery Expert Opin. Drug Deliv. 3 2 2006 205 216 (Pubitemid 43338092)
52. M.E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol. Pharm. 6 3 2009 659 668
53. M.G. Harisinghani, J. Barentsz, P.F. Hahn, W.M. Deserno, S. Tabatabaei, C.H. van de Kaa, J. de la Rosette, and R. Weissleder Noninvasive detection of clinically occult lymph-node metastases in prostate cancer N. Engl. J. Med. 348 25 2003 2491 2499 (Pubitemid 36706536)
54. H. Devalapally, Z. Duan, M. Seiden, and M. Amiji Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles Clin. Cancer Res. 14 10 2008 3193
55. L. Jabr-Milane, L. van Vlerken, S. Yadav, and M. Amiji Multi-functional nanocarriers to overcome tumor drug resistance Cancer Treat. Rev. 34 7 2008 592 602
56. L. van Vlerken, Z. Duan, M. Seiden, and M. Amiji Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer Cancer Res. 67 10 2007 4843
57. D. Shenoy, and M. Amiji Poly (ethylene oxide)-modified poly (- caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer Int. J. Pharm. 293 1-2 2005 261 270 (Pubitemid 40381098)
58. S. Ganta, H. Devalapally, A. Shahiwala, and M. Amiji A review of stimuli-responsive nanocarriers for drug and gene delivery J. Control. Release 126 3 2008 187 204
59. A. Thierry, D. Vige, S. Coughlin, J. Belli, A. Dritschilo, and A. Rahman Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes FASEB J. 7 6 1993 572
60. S. Kommareddy, and M. Amiji Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery Nanomedicine 3 1 2007 32 42 (Pubitemid 46428185)
61. S. Yadav, L. van Vlerken, S. Little, and M. Amiji Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells Cancer Chemother. Pharmacol. 63 4 2009 711 722
62. S. Kommareddy, S.B. Tiwari, and M.M. Amiji Long-circulating polymeric nanovectors for tumor-selective gene delivery Technol. Cancer Res. Treat. 4 6 2005 615 625 (Pubitemid 43083345)
63. L.E.v. Vlerken, T.K. Vyas, and M.M. Amiji Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery Pharm. Res. 24 8 2007 1405 1414 (Pubitemid 46988224)
64. H. Hamada, K. Miura, K. Ariyoshi, Y. Heike, S. Sato, K. Kameyama, Y. Kurosawa, and T. Tsuruo Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein Cancer Res. 50 11 1990 3167
65. F. Marcucci, and F. Lefoulon Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress Drug Discov. Today 9 5 2004 219 228 (Pubitemid 38230021)
66. T. Iwahashi, E. Okochi, K. Ariyoshi, H. Watabe, E. Amann, S. Mori, T. Tsuruo, and K. Ono Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model Cancer Res. 53 22 1993 5475
67. L. De Menezes, E. Daniel, L. Pilarski, and T. Allen In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma Cancer Res. 58 15 1998 3320
68. M. Ghetie, R. Marches, S. Kufert, and E. Vitetta An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line Blood 104 1 2004 178
69. X. Hu, J. Li, E. Yang, S. Vandervalk, and P. Xing Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways Br. J. Cancer 96 6 2007 918
70. L. Rajendran, H. Kn̂lker, and K. Simons Subcellular targeting strategies for drug design and delivery Nat. Rev. Drug Discov. 9 1 2010 29 42
71. V.P. Torchilin Recent approaches to intracellular delivery of drugs and DNA and organelle targeting Annu. Rev. Biomed. Eng. 8 2006 343 375 (Pubitemid 44314821)
72. H. Morimoto, S. Yonehara, and B. Bonavida Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins Cancer Res. 53 11 1993 2591
73. M. Hamidi, A. Azadi, and P. Rafiei Hydrogel nanoparticles in drug delivery Adv. Drug Deliv. Rev. 60 15 2008 1638 1649
74. M. Hamidi, A. Azadi, and P. Rafiei Pharmacokinetic consequences of pegylation Drug Deliv. 13 6 2006 399 409 (Pubitemid 44470219)
75. M. Hamidi, P. Rafiei, and A. Azadi Designing PEGylated therapeutic molecules: advantages in ADMET properties Expert Opin. Drug Discov. 3 11 2008 1293 1307
76. Z. Xu, J. Hoffman, I. Patel, and P. Joubert Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon-2a (IFN-2a) to healthy subjects Hepatology 28 part 2 1998 702A
77. D.M. Dykxhoorn, and J. Lieberman Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs Annu. Rev. Biomed. Eng. 8 2006 377 402 (Pubitemid 44314822)
78. Y. Zhao, and D. Srivastava A developmental view of microRNA function Trends Biochem. Sci. 32 4 2007 189 197 (Pubitemid 46603281)
79. R.I. Gregory, T.P. Chendrimada, and R. Shiekhattar MicroRNA biogenesis: isolation and characterization of the microprocessor complex Methods Mol. Biol. 342 2006 33 47
80. C. Nieth, A. Priebsch, A. Stege, and H. Lage Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi) FEBS Lett. 545 2-3 2003 144 150 (Pubitemid 36694691)
81. H. Lage MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance Curr. Drug Targets 7 7 2006 813 821
82. H. Lage Therapeutic potential of RNA interference in drug-resistant cancers Future Oncol. 5 2 2009 169 185
83. H. Wu, W.N. Hait, and J.M. Yang Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells Cancer Res. 63 7 2003 1515 1519 (Pubitemid 36373637)
84. H. Xiao, Z. Wu, H. Shen, A.L. Luo, Y.F. Yang, X.B. Li, and D.Y. Zhu In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi Basic Clin. Pharmacol. Toxicol. 103 4 2008 342 348
85. U. Stein, W. Walther, A. Stege, A. Kaszubiak, I. Fichtner, and H. Lage Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA Mol. Ther. 16 1 2008 178 186
86. M. Saad, O.B. Garbuzenko, and T. Minko Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer Nanomedicine (Lond) 3 6 2008 761 776
87. R.N. Kolesnick, and M. Kronke Regulation of ceramide production and apoptosis Annu. Rev. Physiol. 60 1998 643 665
88. A.P. Struckhoff, R. Bittman, M.E. Burow, S. Clejan, S. Elliott, T. Hammond, Y. Tang, and B.S. Beckman Novel ceramide analogs as potential chemotherapeutic agents in breast cancer J. Pharmacol. Exp. Ther. 309 2 2004 523 532 (Pubitemid 38542603)
89. M. Schenck, A. Carpinteiro, H. Grassme, F. Lang, and E. Gulbins Ceramide: physiological and pathophysiological aspects Arch. Biochem. Biophys. 462 2 2007 171 175 (Pubitemid 46856326)
90. B.J. Pettus, C.E. Chalfant, and Y.A. Hannun Ceramide in apoptosis: an overview and current perspectives Biochim. Biophys. Acta 1585 2-3 2002 114 125 (Pubitemid 36092075)
91. E. Gulbins, and H. Grassme Ceramide and cell death receptor clustering Biochim. Biophys. Acta 1585 2-3 2002 139 145 (Pubitemid 36092078)
92. M.J. Elrick, S. Fluss, and M. Colombini Sphingosine, a product of ceramide hydrolysis, influences the formation of ceramide channels Biophys. J. 91 5 2006 1749 1756 (Pubitemid 44352439)
93. L.J. Siskind Mitochondrial ceramide and the induction of apoptosis J. Bioenerg. Biomembr. 37 3 2005 143 153 (Pubitemid 41420469)
94. L.J. Siskind, R.N. Kolesnick, and M. Colombini Ceramide forms channels in mitochondrial outer membranes at physiologically relevant concentrations Mitochondrion 6 3 2006 118 125 (Pubitemid 43872021)
95. M. Itoh, T. Kitano, M. Watanabe, T. Kondo, T. Yabu, Y. Taguchi, K. Iwai, M. Tashima, T. Uchiyama, and T. Okazaki Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia Clin. Cancer Res. 9 1 2003 415 423 (Pubitemid 36109759)
96. H. Morjani, N. Aouali, R. Belhoussine, R.J. Veldman, T. Levade, and M. Manfait Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets Int. J. Cancer 94 2 2001 157 165 (Pubitemid 32911407)
97. A. Senchenkov, D.A. Litvak, and M.C. Cabot Targeting ceramide metabolism - a strategy for overcoming drug resistance J. Natl. Cancer Inst. 93 5 2001 347 357 (Pubitemid 32229379)
98. L.E. van Vlerken, Z. Duan, S.R. Little, M. Seiden, and M.M. Amiji Augmentation of therapeutic efficacy in drug resistant tumor models using ceramide co-administration in temporal-controlled polymer-blend nanoparticle delivery systems The AAPS Journal 12 2 2010 171 180
99. L.E. van Vlerken, Z. Duan, S.R. Little, M.V. Seiden, and M.M. Amiji Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model Mol. Pharm. 5 4 2008 516 526
100. Y.Y. Liu, T.Y. Han, A.E. Giuliano, and M.C. Cabot Ceramide glycosylation potentiates cellular multidrug resistance FASEB J. 15 3 2001 719 730 (Pubitemid 32245990)
101. V. Gouaze, Y.Y. Liu, C.S. Prickett, J.Y. Yu, A.E. Giuliano, and M.C. Cabot Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs Cancer Res. 65 9 2005 3861 3867 (Pubitemid 40616367)
102. B. Altenberg, and K.O. Greulich Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes Genomics 84 6 2004 1014 1020 (Pubitemid 39469126)
103. P.P. Hsu, and D.M. Sabatini Cancer cell metabolism: Warburg and beyond Cell 134 5 2008 703 707
104. M. Lopez-Lazaro The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med. Chem. 8 3 2008 305 312 (Pubitemid 351761435)
105. O. Warburg On respiratory impairment in cancer cells Science 124 3215 1956 269 270
106. C.D. Young, and S.M. Anderson Sugar and fat - that's where it's at: metabolic changes in tumors Breast Cancer Res. 10 1 2008 202
107. P.T. Schumacker Reactive oxygen species in cancer cells: live by the sword, die by the sword Cancer Cell 10 3 2006 175 176 (Pubitemid 44311072)
108. H. Liu, N. Savaraj, W. Priebe, and T.J. Lampidis Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C) Biochem. Pharmacol. 64 12 2002 1745 1751 (Pubitemid 35351581)
109. H. Lu, R.A. Forbes, and A. Verma Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis J. Biol. Chem. 277 26 2002 23111 23115 (Pubitemid 34952134)
110. J.J. Lum, T. Bui, M. Gruber, J.D. Gordan, R.J. DeBerardinis, K.L. Covello, M.C. Simon, and C.B. Thompson The transcription factor HIF-1 alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis Genes Dev. 21 9 2007 1037 1049 (Pubitemid 46686473)
111. I.F. Robey, A.D. Lien, S.J. Welsh, B.K. Baggett, and R.J. Gillies Hypoxia-inducible factor-1 alpha and the glycolytic phenotype in tumors Neoplasia 7 4 2005 324 330 (Pubitemid 40664221)
112. S.P. Mathupala, Y.H. Ko, and P.L. Pedersen Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria Oncogene 25 34 2006 4777 4786 (Pubitemid 44187625)
113. P.L. Pedersen Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen J. Bioenerg. Biomembr. 39 3 2007 211 222 (Pubitemid 47619382)
114. P.L. Pedersen Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment's roles together with hexokinase-2 in the "Warburg effect" in cancer J. Bioenerg. Biomembr. 40 3 2008 123 126
115. A. Floridi, M.G. Paggi, S. D'Atri, C. De Martino, M.L. Marcante, B. Silvestrini, and A. Caputo Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells Cancer Res. 41 11 Pt 1 1981 4661 4666 (Pubitemid 12201388)
116. G. Giorgioni, S. Ruggieri, A. Di Stefano, P. Sozio, B. Cinque, L. Di Marzio, G. Santoni, and F. Claudi Glycosyl and polyalcoholic prodrugs of lonidamine Bioorg. Med. Chem. Lett. 18 7 2008 2445 2450 (Pubitemid 351442886)
117. L. Ravagnan, I. Marzo, P. Costantini, S.A. Susin, N. Zamzami, P.X. Petit, F. Hirsch, M. Goulbern, M.F. Poupon, L. Miccoli, Z. Xie, J.C. Reed, and G. Kroemer Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore Oncogene 18 16 1999 2537 2546 (Pubitemid 29216676)
118. A. Jordan, R. Scholz, P. Wust, H. FaKhling, and R. Felix Magnetic Fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles J. Magn. Magn. Mater. 201 1 1999 413 419
119. G. Kong, R.D. Braun, and M.W. Dewhirst Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size Cancer Res. 60 16 2000 4440 4445 (Pubitemid 32103623)
120. M.H. Gaber Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia J. Biochem. Mol. Biol. Biophys. 6 5 2002 309 314 (Pubitemid 35264648)
121. N. Rapoport Combined cancer therapy by micellar-encapsulated drug and ultrasound Int. J. Pharm. 277 1-2 2004 155 162 (Pubitemid 38670430)
122. A. Marin, H. Sun, G.A. Husseini, W.G. Pitt, D.A. Christensen, and N.Y. Rapoport Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake J. Control. Release 84 1-2 2002 39 47 (Pubitemid 35223412)
123. Y.N. Konan, R. Gurny, and E. Allemann State of art in the delivery of photosensitizers for photodynamic therapy Photochem. Photobiol. 66 2 2001 89 106
124. A.C. Samia, X. Chen, and C. Burda Semiconductor quantum dots for photodynamic therapy J. Am. Chem. Soc. 125 51 2003 15736 15737 (Pubitemid 37553678)
125. W. Tang, H. Xu, R. Kopelman, and M. Philbert Photodynamic characterisation and in vitro application of methylene blue containing nanoparticle platform Photochem. Photobiol. 81 2 2004 242 249 (Pubitemid 40551499)